Fig. 2: Characterization and integration of plasma cell clusters. | Nature Communications

Fig. 2: Characterization and integration of plasma cell clusters.

From: 1q amplification and PHF19 expressing high-risk cells are associated with relapsed/refractory multiple myeloma

Fig. 2

A Canonical translocations, mutations, and copy number alteration marker gene expression in each patient. B Final clusters determined from the dataset integration of 49 samples. C Diagnosis of the patient from which each cell was derived overlaid on to the integrated clusters. D Significant associations between clusters and clinical/genomic covariates (one-sided t-tests). E Percentage of each cluster from SMM, NDMM, and RRMM patients. RRPC clusters are boxed in red (D, E). F Proportion of RRPCs in patients stratified by diagnosis (one-sided t-test p-values: NDMMvSMM P = 8.26E−3, RRMMvNDMM P = 8.18E−4, RRMMvSMM P = 2.17E−5). G Proportion of RRPC11 in patients stratified by 1q copy number (one-sided t-test p-values: 2v3+ P = 2.96E−2, 2v4 P = 7.49E−3, 3v4+ P = 1.40E−3). H Proportion of RRPC11 in patients stratified by TP53 mutation status (one-sided t-test p-value: WTvMut P = 2.45E−2). I Proportion of RRPC11 in patients with Gain/Amp1q, TP53 mutations, or both (one-sided t-test p-values: WTv1q P = 8.11E−2, WTv[1q or Mut(TP53)] P = 3.50E−2, WTv[1q and Mut(TP53)] P = 4.85E−2, 1qv[1q and Mut(TP53)] P = 9.19E−2). Significance levels are: P < 0.1: (\(\cdot\)), P < 0.05: *, P < 0.01 (**), P < 0.001 (***).

Back to article page